TenAces Biosciences develops rationally designed molecular glue therapeutics for enhanced targeted protein degradation. The company uses a data-centric machine learning platform to identify naturally occurring protein interactions and predict new molecular glues for treating a range of diseases. It was launched in January 2024 by AION Labs.